The aim of the present study was to determine whether dual PPARα/γ agonist tesaglitazar attenuates NAFLD and atherosclerosis development in diabetic low-density lipoprotein receptor-deficient (LDLr−/−) mice. Here, VLDLR is linked to metabolic dysfunction-associated steatotic liver disease.